Your browser doesn't support javascript.
loading
Nebulized Tranexamic Acid Therapy for Hemoptysis Associated with Submassive Pulmonary Embolism.
Dhanani, Jayesh A; Roberts, Jason; Reade, Michael C.
Afiliação
  • Dhanani JA; UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Roberts J; Department of Intensive Care Medicine, Royal Brisbane & Women's Hospital, Brisbane, Australia.
  • Reade MC; Burns, Trauma and Critical Care Research Centre, University of Queensland, Brisbane, Australia.
J Aerosol Med Pulm Drug Deliv ; 33(1): 12-14, 2020 02.
Article em En | MEDLINE | ID: mdl-31161941
ABSTRACT
Hemoptysis and pulmonary embolism (PE) are life-threatening pulmonary emergencies that, when present together, create a therapeutic conundrum. We present an illustrative case of a 65-year-old man with unprovoked submassive PE and moderate hemoptysis due to pulmonary infarction. Hemoptysis precluded systemic anticoagulation. Failing a conservative management strategy, we administered nebulized tranexamic acid. After four doses of nebulized tranexamic acid 500 mg, 6 hours apart, hemoptysis had ceased. Systemic anticoagulation with intravenous heparin was then successfully commenced 12 hours after the last episode of hemoptysis. The patient was weaned off high-flow nasal oxygen therapy over the course of the next 5 days with no hemoptysis recurrence. Noting the absence of trial evidence, but good pharmacological rationale and our positive experience, we suggest tranexamic acid is a useful noninvasive treatment option for the management of such conditions. Consent for this publication was obtained from the patient.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Ácido Tranexâmico / Hemoptise Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Ácido Tranexâmico / Hemoptise Idioma: En Ano de publicação: 2020 Tipo de documento: Article